High-density lipoprotein cholesterol raising: does it matter?

Area of Science:

• Cardiology
• Biochemistry
• Public Health

Background:

• Cardiovascular disease (CVD) is a major global health concern, with high-density lipoprotein cholesterol (HDL-C) recognized as a key predictor of cardiovascular events.
• Low HDL-C levels pose a residual risk, even in patients with controlled low-density lipoprotein cholesterol (LDL-C).
• Previous research suggested raising HDL-C as a potential therapeutic strategy due to strong epidemiological and biological evidence.

Purpose of the Study:

• To evaluate the effectiveness of HDL-C raising therapies in improving cardiovascular outcomes.
• To examine the role of HDL-C levels versus HDL functionality in cardiovascular risk.
• To inform future therapeutic strategies for managing cardiovascular disease.

Main Methods:

• Analysis of three large randomized clinical trials.
• Investigation of HDL-C raising agents (niacin and dalcetrapib) in statin-treated patients.
• Assessment of cardiovascular outcomes in relation to HDL-C levels and therapeutic interventions.

Main Results:

• Recent large-scale clinical trials failed to show improved cardiovascular outcomes with HDL-C raising agents like niacin and dalcetrapib.
• These findings challenge the previous assumption that simply increasing HDL-C levels is beneficial.
• The results suggest that the effectiveness of HDL-C interventions may depend on factors beyond plasma concentration.

Conclusions:

• HDL functionality, rather than plasma HDL-C levels, appears to be more critical for cardioprotection.
• Future therapeutic approaches should aim to enhance HDL functionality.
• Developing agents that improve HDL's biological activity is crucial for effective CVD management.